Therapeutic Focus
Patient-informed discovery and patient-driven development
Patients are central to our mission at Fulcrum. Partnering with the patient community is also essential to our process. Our drug discovery begins with a deep exploration of disease biology in patient tissue samples. As we advance a program, the patient voice guides our development strategy.
Our lead program, pociredir, is being investigated in clinical trials to treat sickle cell disease (SCD). We are developing small molecules to improve the lives of patients with genetically defined diseases.
Inspired by patients
At Fulcrum, we are driven by a commitment to make a difference for patients with genetically defined diseases. We have been privileged to spend time with many of these patients and their families. Their experiences guide us as we work to develop therapies that will lead to meaningful improvements in their day-to-day lives. Read more about the patients who inspire us.
Sickle Cell Disease
Kadeem
Boston, Massachusetts | Born May 1989
“It’s hard for sickle cell patients to get their voices heard… We have an invisible disability. That’s what my poetry aims to express.”
Kadeem has spent his life navigating between periods of normal functioning and periods of hospitalization, seclusion and anxiety due to sickle cell disease (SCD). As a teenager, he began to let his mind play with words, rhythms and sounds. Over the years, spreading awareness about SCD through poetry and advocacy has become Kadeem’s medicine of choice.